TY - STD TI - Pradaxa ® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014. ID - ref1 ER - TY - JOUR AU - Connolly, S. J. AU - Ezekowitz, M. D. AU - Yusuf, S. AU - Eikelboom, J. AU - Oldgren, J. AU - Parekh, A. PY - 2009 DA - 2009// TI - Dabigatran versus warfarin in patients with atrial fibrillation JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0905561 DO - 10.1056/NEJMoa0905561 ID - Connolly2009 ER - TY - JOUR AU - Díaz, M. Q. AU - Borobia, A. M. AU - Núñez, M. A. R. AU - Virta, A. M. M. AU - Fabra, S. AU - Casado, M. S. PY - 2013 DA - 2013// TI - Use of prothrombin complex concentrates for urgent reversal of dabigatran in the emergency department JO - Haematologica VL - 98 UR - https://doi.org/10.3324/haematol.2013.092767 DO - 10.3324/haematol.2013.092767 ID - Díaz2013 ER - TY - JOUR AU - Stangier, J. AU - Rathgen, K. AU - Stahle, H. AU - Mazur, D. PY - 2010 DA - 2010// TI - Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate JO - Clin Pharmacokinet VL - 49 UR - https://doi.org/10.2165/11318170-000000000-00000 DO - 10.2165/11318170-000000000-00000 ID - Stangier2010 ER - TY - JOUR AU - Blech, S. AU - Ebner, T. AU - Ludwig-Schwellinger, E. AU - Stangier, J. AU - Roth, W. PY - 2008 DA - 2008// TI - The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans JO - Drug Metab Dispos VL - 36 UR - https://doi.org/10.1124/dmd.107.019083 DO - 10.1124/dmd.107.019083 ID - Blech2008 ER - TY - JOUR AU - Ryn, J. AU - Stangier, J. AU - Haertter, S. AU - Liesenfeld, K. AU - Wienen, W. AU - Feuring, M. PY - 2010 DA - 2010// TI - Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity JO - Thromb Haemost VL - 103 UR - https://doi.org/10.1160/TH09-11-0758 DO - 10.1160/TH09-11-0758 ID - Ryn2010 ER - TY - JOUR AU - January, C. T. AU - Wann, L. S. AU - Alpert, J. S. AU - Calkins, H. AU - Cleveland, J. C. AU - Cigarroa, J. E. PY - 2014 DA - 2014// TI - 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary JO - Circulation VL - 130 UR - https://doi.org/10.1161/CIR.0000000000000040 DO - 10.1161/CIR.0000000000000040 ID - January2014 ER - TY - JOUR AU - Bloom, B. AU - Eng, B. AU - Filion, K. AU - Atallah, R. AU - Eisenberg, M. PY - 2014 DA - 2014// TI - Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran JO - Am J Card VL - 113 UR - https://doi.org/10.1016/j.amjcard.2013.11.049 DO - 10.1016/j.amjcard.2013.11.049 ID - Bloom2014 ER - TY - JOUR AU - Ryn, J. AU - Ruehl, D. AU - Priepke, H. AU - Hauel, N. AU - Wienen, W. PY - 2008 DA - 2008// TI - Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Abstract presented at: 13th Congress of the European Hematology Association JO - Haematologica VL - 93 ID - Ryn2008 ER - TY - JOUR AU - Pragst, I. AU - Zeitler, H. AU - Doerr, B. AU - Kaspereit, F. J. AU - Herzog, E. AU - Dickneite, G. PY - 2012 DA - 2012// TI - Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model JO - J Thromb Haemost VL - 10 UR - https://doi.org/10.1111/j.1538-7836.2012.04859.x DO - 10.1111/j.1538-7836.2012.04859.x ID - Pragst2012 ER - TY - JOUR AU - Hoffman, M. AU - Volovyk, Z. AU - Monroe, D. M. PY - 2015 DA - 2015// TI - Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate JO - Anesthesiology VL - 122 UR - https://doi.org/10.1097/ALN.0000000000000540 DO - 10.1097/ALN.0000000000000540 ID - Hoffman2015 ER - TY - JOUR AU - Lambourne, M. D. AU - Eltringham-Smith, L. J. AU - Gataiance, S. AU - Arnold, D. M. AU - Crowther, M. A. AU - Sheffield, W. P. PY - 2012 DA - 2012// TI - Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate JO - J Thromb Haemost VL - 10 UR - https://doi.org/10.1111/j.1538-7836.2012.04863.x DO - 10.1111/j.1538-7836.2012.04863.x ID - Lambourne2012 ER - TY - JOUR AU - Zhou, W. AU - Schwarting, S. AU - Illanes, S. AU - Liesz, A. AU - Middelhoff, M. AU - Zorn, M. PY - 2011 DA - 2011// TI - Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran JO - Stroke VL - 42 UR - https://doi.org/10.1161/STROKEAHA.111.624650 DO - 10.1161/STROKEAHA.111.624650 ID - Zhou2011 ER - TY - JOUR AU - Eerenberg, E. AU - Kamphuisen, P. AU - Sijpkens, M. AU - Meijers, J. AU - Buller, H. AU - Levi, M. PY - 2011 DA - 2011// TI - Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate JO - Circulation VL - 124 UR - https://doi.org/10.1161/CIRCULATIONAHA.111.029017 DO - 10.1161/CIRCULATIONAHA.111.029017 ID - Eerenberg2011 ER - TY - JOUR AU - Nutescu, E. AU - Dager, W. AU - Kalus, J. AU - Lewin, J. AU - Cipolle, M. PY - 2013 DA - 2013// TI - Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations JO - Am J Health Syst Pharm VL - 70 UR - https://doi.org/10.2146/ajhp130243 DO - 10.2146/ajhp130243 ID - Nutescu2013 ER - TY - JOUR AU - Kaatz, S. AU - Kouides, P. A. AU - Garcia, D. A. AU - Spyropolous, A. C. AU - Crowther, M. AU - Douketis, J. D. PY - 2012 DA - 2012// TI - Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors JO - Am J Hematol VL - 87 UR - https://doi.org/10.1002/ajh.23202 DO - 10.1002/ajh.23202 ID - Kaatz2012 ER - TY - JOUR AU - Singh, T. AU - Maw, T. AU - Henry, B. AU - Pastor-Soler, N. AU - Unruh, M. AU - Hallows, K. PY - 2013 DA - 2013// TI - Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience JO - Clin J Am Soc Nephrol VL - 8 UR - https://doi.org/10.2215/CJN.01570213 DO - 10.2215/CJN.01570213 ID - Singh2013 ER - TY - JOUR AU - Chang, D. N. AU - Dager, W. E. AU - Chin, A. I. PY - 2013 DA - 2013// TI - Removal of dabigatran by hemodialysis JO - Am J Kidney Dis VL - 61 UR - https://doi.org/10.1053/j.ajkd.2012.08.047 DO - 10.1053/j.ajkd.2012.08.047 ID - Chang2013 ER - TY - STD TI - Multaq ® [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2014. ID - ref19 ER - TY - STD TI - Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grottke O. Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113: ahead of print. ID - ref20 ER - TY - JOUR AU - Grottke, O. AU - Ryn, J. AU - Spronk, H. M. AU - Rossaint, R. PY - 2014 DA - 2014// TI - Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental modeal JO - Crit Care VL - 18 UR - https://doi.org/10.1186/cc13717 DO - 10.1186/cc13717 ID - Grottke2014 ER - TY - STD TI - Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, Lang B, et al. A randomized study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015, 113: ahead of print. ID - ref22 ER -